The U.S. Food and Drug Administration's staff reviewers on Tuesday raised safety concerns that GSK's blood cancer drug Blenrep, when used in combination with other treatments, may cause eye damage in ...

The FDA already is scheduled to decide by Dec. 30 whether the same drug can be used by patients with hypercortisolism, also ...

Treatments for bronchiectasis, chronic immune thrombocytopenia, fibromyalgia, Friedreich ataxia, and recurrent respiratory papillomatosis are under review.

Traditional animal models often fall short of predicting human outcomes. High costs and supply chain limitations (such as ...